STAMICIS

This brand name is authorized in Austria, Estonia, Spain, France, Hong Kong, Ireland, Malta, Singapore, United Kingdom

Active ingredients

The drug STAMICIS contains one active pharmaceutical ingredient (API):

1 Technetium ⁹⁹ᵐTc sestamibi UNII N6OU7HJ70P - TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE

Technetium 99mTc sestamibi is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI. Following intravenous injection of the drug, Technetium 99mTc sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue. Read about Technetium ⁹⁹ᵐTc sestamibi

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
STAMICIS Kit for radiopharmaceutical preparation	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09GA01	Technetium (99mTc) sestamibi	V Various → V09 Diagnostic radiopharmaceuticals → V09G Cardiovascular system → V09GA Technetium (99mTc) compounds
Discover more medicines within V09GA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1393983
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 71081
Country: FR	Base de données publique des médicaments	Identifier(s): 65679296
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 395348
Country: HK	Department of Health Drug Office	Identifier(s): 57910
Country: MT	Medicines Authority	Identifier(s): AA826/00202
Country: SG	Health Sciences Authority	Identifier(s): 14129P